ReviewCancer immunology, immunotherapy : CII2005
Tumor counterattack: fact or fiction?
Review in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 92 citations in OpenAlex.
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.Cancers · 2024Review
- The dual role of the CD95 and CD95L signaling pathway in glioblastoma.Frontiers in immunology · 2022Review
- Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.Molecular diagnosis & therapy · 2021Review
- Influence of Microgravity on Apoptosis in Cells, Tissues, and Other Systems In Vivo and In Vitro.International journal of molecular sciences · 2020Review
- Article
- Differential in vivo biodistribution ofNanomedicine : nanotechnology, biology, and medicine · 2019Article
- Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.Frontiers in immunology · 2019Review
- Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.Journal of cancer research and clinical oncology · 2018Article
- Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.Cancer biology & therapy · 2017Article
- Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Cancer biology & therapy · 2017Review
- Dual role of macrophages in the response of C26 colon carcinoma cells to 5-fluorouracil administration.Oncology letters · 2016Article
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Oncoimmunology · 2015Review
- The role of CD95 and CD95 ligand in cancer.Cell death and differentiation · 2015Review
- In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.Frontiers in oncology · 2015Article
- Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.Molecular and clinical oncology · 2015Article
- Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.Cancer immunology, immunotherapy : CII · 2012Article
- Stimulation of FasL induces production of proinflammatory mediators through activation of mitogen-activated protein kinases and nuclear factor-κB in THP-1 cells.Inflammation · 2012Article
- Article
- Cytomegalovirus and tumors: two players for one goal-immune escape.The open virology journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer development relies on a variety of mechanisms that facilitate tumor growth despite the presence of a functioning immune system. Understanding these mechanisms may foster novel therapeutic approaches for oncology and organ transplantation. By expression of the apoptosis-inducing protein CD95L (FasL, APO-1L, CD178), tumors may eliminate tumor-infiltrating lymphocytes and suppress anti-tumor immune responses, a phenomenon called "tumor counterattack". On the one hand, preliminary evidence of tumor counterattack in human tumors exists, and CD95L expression can prevent T-cell responses in vitro. On the other hand, CD95L-expressing tumors are rapidly rejected and induce inflammation in mice. Here, we summarize and discuss the consequences of CD95L expression of tumor cells and its contribution to immune escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.